SOLVE(D) | An IPG Health Company’s Post

💊 Boost Your Pharma R&D Efficiency! 🔍 Uncover the latest strategies and innovations in our comprehensive guide designed to enhance pharmaceutical research and development efficiency. From cutting-edge technologies to process optimization, learn how to streamline operations and accelerate drug development. 🔑 Key Insights: - Discover the latest tools and techniques revolutionizing Pharma R&D. - Understand the impact of AI, machine learning, and data analytics in speeding up drug discovery and trials. - Implement best practices for R&D efficiency to stay ahead in the competitive pharmaceutical landscape. 📈 This in-depth analysis is invaluable for pharma professionals, researchers, and executives aiming to optimize their R&D processes and drive innovation. Stay informed and transform your pharmaceutical R&D approach for better outcomes and faster market delivery! 🔗 Full article 👉 https://bit.ly/48wC9OF #Pharmaceuticals #RnD #Innovation #DrugDevelopment #Pharma #Research

💊 Boost Your Pharma R&D Efficiency! 🔍 Uncover the latest strategies and innovations in our comprehensive guide designed to enhance pharmaceutical research and development efficiency. From cutting-edge technologies to process optimization, learn how to streamline operations and accelerate drug development. 🔑 Key Insights: - Discover the latest tools and techniques revolutionizing Pharma R&D. - Understand the impact of AI, machine learning, and data analytics in speeding up drug discovery and trials. - Implement best practices for R&D efficiency to stay ahead in the competitive pharmaceutical landscape. 📈 This in-depth analysis is invaluable for pharma professionals, researchers, and executives aiming to optimize their R&D processes and drive innovation. Stay informed and transform your pharmaceutical R&D approach for better outcomes and faster market delivery! 🔗 Full article 👉 https://lnkd.in/e4sg7BWy #Pharmaceuticals #RnD #Innovation #DrugDevelopment #Pharma #Research

📣 ”AI will radically transform the pharmaceutical industry” – sure, but how exactly? This is how ⬇️ Yesterday’s seminar “How is AI transforming the pharmaceutical industry?” was a deep dive into the transformative impact of AI in the complete pharmaceutical value chain. Stellar lineup of national and international experts from industry, academia, and spin-outs. Each speaker provided insightful perspectives on the possibilities and challenges associated with using AI in the pharmaceutical value chain. 🚀 Jens Christian Nielsen from Gubra talked us through how they use Alphafold and AI in drug discovery and Mark Nicholas Jones from Quantum Solutions on their efforts to develop a software-as-a-lab approach to bridge the gap between lab operations and quantum chemistry. Highlights for me were Paula Antunes' presentation on the complexity of regulating AI, digital health, and pharmaceuticals in conjunction as well as Mads Nielsen's presentation of the PHAIR project. 🌟 A big shout-out to Mie Kristensen & Stine Rønholt for organizing in collaboration with the Danish Pharmaceutical Society. 👏 #AI #Pharmaceuticals #Healthcare #Innovation #FutureOfHealthcare https://lnkd.in/gmqtWZSq

Ten Commandments of Drug R&D Pharmaceutical R&D is a very low-velocity, high-cost process, which makes it hard for any individual to gather the large body of experience required to make better decision-making. However, there is lot to be gained through the appreciation of some simple truisms accumulated by the truly seasoned practitioners of drug R&D. One of those practitioners is Dr Phillip Needleman. Click on the link to keep reading. https://lnkd.in/gPHPByfr 1) “There’s only one Nobel prize…” and industry researchers aren’t likely to get it 2) “Phenomenology is very different than pharmacology” 3) “Anything put on hold is dead” 4) “Define and do the Killer experiments” 5) “If you don’t know where you are going, all roads will get you there” 6) “Make sure it’s doable in my lifetime” 7) “Find the shortest route to heaven” 8) “I’m from Missouri… show me data” 9) “Mechanisms should become lifecycle management platforms” 10) “The world belongs to finishers” Here is the link again https://lnkd.in/gPHPByfr

Interesting article on how big pharmas can be more efficient and how R&D performance can be evaluated using a set of metrics.

The #pharmaceutical landscape is rapidly evolving with small molecule active pharmaceutical ingredients (APIs) at the forefront. The full report offers invaluable insights into the small molecule #API market’s growth, projected to reach $82.6 billion by 2027! As a #digitalmarketer for a small (but powerful!) chemical manufacturer, I want us to stay ahead of the curve in drug development by embracing these emerging trends. Here are a couple trends that stuck out to me: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙗𝙮 𝙎𝙢𝙖𝙡𝙡 𝘽𝙪𝙨𝙞𝙣𝙚𝙨𝙨𝙚𝙨 (#SMB): Small pharmaceutical companies are making big waves, accounting for a majority of FDA-approved new molecular entities (NMEs) and driving clinical pipeline growth. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨: Advancements in #genomics and disease pathways are steering the shift from empirical discovery to targeted, data-driven development. 𝘿𝙞𝙜𝙞𝙩𝙖𝙡𝙞𝙯𝙖𝙩𝙞𝙤𝙣 & 𝙃𝙞𝙜𝙝-𝙏𝙝𝙧𝙤𝙪𝙜𝙝𝙥𝙪𝙩 𝙎𝙘𝙧𝙚𝙚𝙣𝙞𝙣𝙜: Cutting-edge digital tools and high-throughput experimentation accelerate the R&D process, enhancing efficiency and predictive capabilities. This was a fascinating read that dives into some of the key trends shaping the #discovery and #development of these potent compounds. I'll be attending the upcoming 2024 #DrugDiscoveryChemistry conference where I hope to learn more about similar market trends! Happy reading! ----- #smallpharma #pharma #drugdiscovery #drugresearch #drugdiscoverychemistry #chemicalinnovation #medicinalchemistry #smallmolecules #innovation #markets #digitalmarketing

#AROs #CROs #Pharma #Research Pharmaceutical companies are moving to work more with academic centers to reduce their risk exposure. Drug companies are increasingly looking to academics in a bid to mitigate some of these financial burdens. This often involves university researchers doing early-stage drug discovery before pharmaceutical companies take over to push a novel compound through clinical trials and get it to market. “This trend is not entirely new,” “But it does have momentum now.” My Musings : This shift from inhouse Research , shifting Research at CROs to AROs (Academic Research Organisations) is much needed. Move is desired not purely from a financial viability perspective but the Value that AROs can bring to the table thru their multidisciplinary, interdisciplinary teams support. Lot of Industrial Research used to happen at AROs inside academic campuses till 1960s or 70s. Around the same time CROs came into picture and became stronger since 70s, 80s. It's time to move portion of the industry Research to Academia. Academia can make Research more agile https://lnkd.in/gGcBswhS

Harnessing AI's power to revolutionize drug development. Capturing the potential of genomics and AI in pharmaceuticals. #GenAIDrugDevelopment #AIinPharma #BiotechInnovation #GenomicsResearch #FutureOfMedicine #Femtosoftitservices https://lnkd.in/dcgVmKpz

Pharma founders, this is eye-opening. Some lessons to beat your competition are: ✅ Use the right AI tool/partner ✅ Select the Right People ✅ Engage the Right People frequently ✅ Retain the Right People ✅ Don't relinquish control to an external CEO #pharmaceuticals #leadership ------------------------------- 🦋 𝗣𝗵𝗮𝗿𝗺𝗮 𝗙𝗼𝘂𝗻𝗱𝗲𝗿𝘀 hire me to achieve sustainable growth & talent.  𝗕𝗼𝘁𝘁𝗼𝗺 𝗹𝗶𝗻𝗲, they double their revenues in 2years or less, guaranteed. Like this post?  Want to see more?  📄 Go to my LinkedIn profile and click "+ Follow" 🔔 Click the Bell (appears after you click Follow) 🔘 Select ALL Follow #ProducingProfitablePeople 🔝 Connect with me

How will #regulatory decisions and guidance released in 2024 shape your #ADME research in the coming year? Pharma's Almanac peered into the future to answer this question, gathering a “Roundtable” of leaders within the #pharma and #lifesciences industry to gain insight into the potential shifts in the regulatory environment in 2024. Our VP of Scientific Consulting, Brian Ogilvie, Ph.D., noted that the ICH’s final “Drug Interaction Studies,” slated for release in April, will have a profound impact on #invitro drug interaction studies, allowing pharma companies to take a single approach. The result of the ‘all in one’ method will streamline the approach for evaluating potential for #druginteractions and will expedite the timeline to get drugs approved on multiple markets. Explore Dr. Ogilvie’s full thoughts and #2024predictions from dozens of industry leaders. ⬇️https://hubs.ly/Q02fBFl90